Department of Internal Medicine, University Hospital Basel, Basel, Switzerland.
Circulation. 2012 Jul 3;126(1):31-40. doi: 10.1161/CIRCULATIONAHA.112.100867. Epub 2012 May 23.
We hypothesized that high-sensitivity cardiac troponin (hs-cTn) and its early change are useful in distinguishing acute myocardial infarction (AMI) from acute cardiac noncoronary artery disease.
In a prospective, international multicenter study, hs-cTn was measured with 3 assays (hs-cTnT, Roche Diagnostics; hs-cTnI, Beckman-Coulter; hs-cTnI Siemens) in a blinded fashion at presentation and serially thereafter in 887 unselected patients with acute chest pain. Accuracy of the combination of presentation values with serial changes was compared against a final diagnosis adjudicated by 2 independent cardiologists. AMI was the adjudicated final diagnosis in 127 patients (15%); cardiac noncoronary artery disease, in 124 (14%). Patients with AMI had higher median presentation values of hs-cTnT (0.113 μg/L [interquartile range, 0.049-0.246 μg/L] versus 0.012 μg/L [interquartile range, 0.006-0.034 μg/L]; P<0.001) and higher absolute changes in hs-cTnT in the first hour (0.019 μg/L [interquartile range, 0.007-0.067 μg/L] versus 0.001 μg/L [interquartile range, 0-0.003 μg/L]; P<0.001) than patients with cardiac noncoronary artery disease. Similar findings were obtained with the hs-cTnI assays. Adding changes of hs-cTn in the first hour to its presentation value yielded a diagnostic accuracy for AMI as quantified by the area under the receiver-operating characteristics curve of 0.94 for hs-cTnT (0.92 for both hs-cTnI assays). Algorithms using ST-elevation, presentation values, and changes in hs-cTn in the first hour accurately separated patients with AMI and those with cardiac noncoronary artery disease. These findings were confirmed when the final diagnosis was readjudicated with the use of hs-cTnT values and validated in an independent validation cohort.
The combined use of hs-cTn at presentation and its early absolute change excellently discriminates between patients with AMI and those with cardiac noncoronary artery disease.
URL: http://www.clinicaltrials.gov. Unique identifier: NCT00470587.
我们假设高敏心肌肌钙蛋白(hs-cTn)及其早期变化有助于鉴别急性心肌梗死(AMI)与急性非冠状动脉心脏疾病。
在一项前瞻性、国际性多中心研究中,对 887 例急性胸痛的未选择患者以盲法在就诊时和此后连续检测 3 种检测方法(罗氏诊断 hs-cTnT、贝克曼库尔特 hs-cTnI、西门子 hs-cTnI)测量 hs-cTn。通过 2 位独立心脏病专家裁决的最终诊断对就诊值与连续变化组合的准确性进行比较。AMI 为 127 例患者(15%)的最终裁决诊断;非冠状动脉心脏疾病为 124 例患者(14%)。AMI 患者 hs-cTnT 的就诊中位值更高(0.113μg/L [四分位距,0.049-0.246μg/L] 与 0.012μg/L [四分位距,0.006-0.034μg/L];P<0.001),且 hs-cTnT 在第 1 小时的绝对变化更高(0.019μg/L [四分位距,0.007-0.067μg/L] 与 0.001μg/L [四分位距,0-0.003μg/L];P<0.001)。hs-cTnI 检测结果也得到了类似的发现。将第 1 小时 hs-cTn 的变化值加入就诊值可提高 AMI 的诊断准确性,其曲线下面积为 0.94(hs-cTnI 两种检测方法均为 0.92)。使用 ST 段抬高、就诊值和第 1 小时 hs-cTn 的变化值的算法可准确区分 AMI 患者与非冠状动脉心脏疾病患者。当使用 hs-cTnT 值重新裁决最终诊断并在独立验证队列中进行验证时,证实了这些发现。
hs-cTn 在就诊时的检测值及其早期的绝对变化联合使用可极好地鉴别 AMI 患者与非冠状动脉心脏疾病患者。